Factors affecting dialysis duration in children with Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome

被引:0
|
作者
Khalid, Myda [1 ]
Miller, Chloe [1 ]
Gebregziabher, Netsanet [2 ]
Guckien, Zoe [1 ]
Goswami, Shrea [1 ]
Perkins, Anthony [2 ]
Andreoli, Sharon Phillips [1 ]
机构
[1] Indiana Univ, Sch Med, James Whitcomb Riley Hosp Children, Indianapolis, IN 46202 USA
[2] Indiana Univ, Sch Med, Dept Biostat & Hlth Data Sci, Indianapolis, IN USA
关键词
Shiga toxin-producing Escherichia coli; Hemolytic uremic syndrome; Children; Dialysis; STEC-HUS; NSAID; Hematocrit; White blood cell count; Platelet count; PLATELET TRANSFUSIONS; DIARRHEA; INVOLVEMENT; NEUTROPHILS; PREDICTORS; STRICTURE; HYDRATION; OUTCOMES; RISK;
D O I
10.1007/s00467-022-05839-0
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background Predicting disease severity can be informative for management of HUS. Dialysis requirement, volume depletion, elevated white blood cell counts, very young age, and use of antimotility agents are known factors associated with severe HUS.Methods A retrospective cohort analysis was performed to identify factors associated with dialysis duration using electronic medical record and chart review of 76 children <= 18 years of age at presentation with STEC-HUS identified through billing data from July 2008 to April 2020 at James Whitcomb Riley Hospital for Children, Indiana University, Indiana.Results Novel findings associated with prolonged dialysis duration were age >= 6 years old at presentation (p = 0.041) and lack of drop in platelets below 60,000/mm(3) anytime during the illness (p = 0.015). In addition, children with NSAID exposure trended longer on dialysis: 15 days with vs. 10 days without (p = 0.117). Known risk factors for severe disease including elevated peak white blood cell (WBC) count and higher hematocrit at presentation were also associated with longer dialysis duration: children with peak WBC > 20,000/mm(3) were on dialysis for 15 vs. 9.5 days (p = 0.002) and in children on dialysis <= 14 days hematocrit at presentation was 29.6% vs. 24.2% (p = 0.03). Children requiring dialysis for 20 days or longer were more likely to be on anti-hypertensive medications (p = 0.025) and have chronic kidney disease at 12-month follow up (p = 0.044).Conclusions Age >= 6, elevated WBC count > 20,000/mm(3), higher hematocrit at presentation, lack of drop in platelets to < 60,000/mm(3), and possibly NSAID exposure during illness are associated with longer dialysis duration in STEC-HUS.
引用
收藏
页码:2753 / 2761
页数:9
相关论文
共 50 条
  • [21] GEnomic characterization of shiga toxin-producing escherichia coli associated with hemolytic uremic syndrome in children from paraguay
    Florentin, M.
    Martinez, J.
    Campos, J.
    Poklepovich, T.
    Orrego, V.
    Alvarez, M.
    Ortiz, F.
    Weiler, N.
    CLINICA CHIMICA ACTA, 2024, 558 : 60 - 60
  • [22] Epidemiology and Characterization of Shiga Toxin-Producing Escherichia Coli of Hemolytic Uremic Syndrome in Argentina
    Torti, Jeronimo F.
    Cuervo, Paula
    Nardello, Andrea
    Pizarro, Marcela
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (08)
  • [23] THE SHIGA-LIKE TOXIN-PRODUCING ESCHERICHIA-COLI AND HEMOLYTIC UREMIC SYNDROME
    CLEARY, TG
    LOPEZ, EL
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1989, 8 (10) : 720 - 724
  • [24] Atypical Hemolytic Uremic Syndrome triggered by Shiga toxin-producing Escherichia coli infection
    Alconcher, Laura
    Bronfen, Sabrina
    Lucarelli, Lucas
    PEDIATRIC NEPHROLOGY, 2024, 39 (01) : S152 - S153
  • [25] Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in children: incidence, risk factors, and clinical outcome
    Ylinen, Elisa
    Salmenlinna, Saara
    Halkilahti, Jani
    Jahnukainen, Timo
    Korhonen, Linda
    Virkkala, Tiia
    Rimhanen-Finne, Ruska
    Nuutinen, Matti
    Kataja, Janne
    Arikoski, Pekka
    Linkosalo, Laura
    Bai, Xiangning
    Matussek, Andreas
    Jalanko, Hannu
    Saxen, Harri
    PEDIATRIC NEPHROLOGY, 2020, 35 (09) : 1749 - 1759
  • [26] CEREBRAL ARTERIOPATHY IN A CASE OF SHIGA TOXIN-PRODUCING ESCHERICHIA COLI HEMOLYTIC UREMIC SYNDROME
    Torres, Marcela
    Schenk, Allyson
    Patel, Ketan
    Bosemani, Madhan
    Tilley, Jo
    PEDIATRIC BLOOD & CANCER, 2023, 70 : S141 - S141
  • [27] Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review
    de Zwart, Paul L.
    Mueller, Thomas F.
    Sparta, Giuseppina
    Luyckx, Valerie A.
    PEDIATRIC NEPHROLOGY, 2024, 39 (05) : 1369 - 1385
  • [28] Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS)
    Khalid, Myda
    Andreoli, Sharon
    PEDIATRIC NEPHROLOGY, 2019, 34 (12) : 2495 - 2507
  • [29] Association between uremic hemolytic syndrome and infection by Shiga toxin-producing Escherichia coli
    Giugno, Silvana Monica
    Bibiloni, Norma
    Rahman, Ricardo
    Miliwebsky, Elizabeth
    Chinen, Isabel
    Rivas, Marta
    ACTA BIOQUIMICA CLINICA LATINOAMERICANA, 2007, 41 (01): : 27 - 33
  • [30] Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS)
    Myda Khalid
    Sharon Andreoli
    Pediatric Nephrology, 2019, 34 : 2495 - 2507